



TITLE: Long-term 5HT3 Antagonist Use for Tinnitus: Clinical Evidence and Guidelines

DATE: 23 June 2014

RESEARCH QUESTIONS

1. What are the clinical benefits and harms of long term (>5 day) 5HT3 antagonist use for the treatment of tinnitus?
2. What are the evidence-based guidelines for the use of 5HT3 antagonists for the treatment of tinnitus?

KEY MESSAGE

One randomized controlled trial was identified regarding the clinical benefits and harms of long term (>5 day) 5HT3 antagonist use for the treatment of tinnitus.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 6), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. The search was also limited to English language documents published between January 1, 2004 and June 17, 2014. Internet links were provided, where available.

RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

One randomized controlled trial was identified regarding the clinical benefits and harms of long term (>5 day) 5HT3 antagonist use for the treatment of tinnitus. No relevant health technology

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. **This report may be used for the purposes of research or private study only.** It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners' own terms and conditions.

assessments, systematic reviews, meta-analyses, non-randomized studies, or evidence-based guidelines were identified.

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

No literature identified.

Randomized Controlled Trials

1. Taslimi S, Vahidi H, Pourvaziri A, Modabbernia A, Fallah AY, Yazdani N, et al. Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study. *Eur Arch Otorhinolaryngol.* 2013 May;270(5):1635-41.
[PubMed: PM23001433](#)

Non-Randomized Studies

No literature identified.

Guidelines and Recommendations

No literature identified.

PREPARED BY:

Canadian Agency for Drugs and Technologies in Health

Tel: 1-866-898-8439

www.cadth.ca